Literature DB >> 12552962

Tumors in organ transplant recipients may give clues to their control by immunity.

S Abgrall1, D Orbach, L Bonhomme-Faivre, S Orbach-Arbouys.   

Abstract

Tumors in solid organ transplant recipients are an important complication of surgery. They can be due to the recurrence of malignancy existing in the recipient prior to transplantation, tumors of donor origin transmitted inadvertently and de novo malignancies. These patients constitute a sort of experimental group in whom the normal immune control of the host has been weakened and can provide valuable information. The reported distribution of the tumors developed in these patients may indicate those whose development is controlled by the immune system. Some of the reported data has been unexpected. For example, patients grafted to treat a primary cancer or in whom an asymptomatic tumor was discovered at the time of transplantation rarely have a recurrence. Many of these were skin tumors, but why the SCC/BCC incidence ratio is far from 1 is unclear. Melanomas are not more frequent among immunosuppressed grafted patients, in spite of the fact that they have specific antigens which could be targets for immune and tumor growth control. Some tumors regress and disappear when the immunosuppression regimen is withdrawn. Tumor types rarely observed in grafted patients are thus immune-insensitive and would not normally regress due to immunotherapy.

Entities:  

Mesh:

Year:  2002        PMID: 12552962

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  TAT-mediated delivery of a DNA repair enzyme to skin cells rapidly initiates repair of UV-induced DNA damage.

Authors:  Jodi L Johnson; Brian C Lowell; Olga P Ryabinina; R Stephen Lloyd; Amanda K McCullough
Journal:  J Invest Dermatol       Date:  2010-10-07       Impact factor: 8.551

2.  Modulation of UVB-induced Carcinogenesis by Activation of Alternative DNA Repair Pathways.

Authors:  Yan Sha; Vladimir Vartanian; Nichole Owen; Stephanie J Mengden Koon; Marcus J Calkins; Courtney S Thompson; Zahra Mirafzali; Sara Mir; Lisa E Goldsmith; Huaping He; Chun Luo; Scott M Brown; Paul W Doetsch; Andy Kaempf; Jeong Y Lim; Amanda K McCullough; R Stephen Lloyd
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.